focus -WSS

focus

author：focus 2025-09-27 16:23:30 - browse：9

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： WATCH: Why do bright lights make us see spots?

WSS

#NeedHerScience: shining a light on gender disparities in medicine

IRA could hurt research into orphan drugs for rare diseases

What would happen to your eyes if you looked at the solar eclipse?

Private equity could exacerbate cardiology's overuse problem, experts fear

Disclosing genetic information: not as worrisome as once feared

Private equity could exacerbate cardiology's overuse problem, experts fear

knowledge

focus

leisure time

Heart attack and stroke risk calculators need revising

White House touts steps to stem shortages of cancer treatments

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA proposes changes to key medical devices approval pathway

How one medical school became remarkably diverse

Colonoscopy at 40? Study finds a possible benefit

Medicare details structure of new drug price negotiation program

Paxlovid study fails to answer questions over benefit for broader groups

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What would happen to your eyes if you looked at the solar eclipse?

entertainment

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Why we need to separate burnout from moral injury in health care

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

FDA panel endorses Alnylam’s heart drug — after picking it apart

Disclosing genetic information: not as worrisome as once feared

White House touts steps to stem shortages of cancer treatments

hotspot

explore

hotspot

Wikipedia